Scott T. Reents - 28 Feb 2023 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, CHIEF FINANCIAL OFFICER
Signature
Steven L. Scrogham, attorney-in-fact for Scott T. Reents
Issuer symbol
ABBV
Transactions as of
28 Feb 2023
Net transactions value
-$4,397,088
Form type
4
Filing time
02 Mar 2023, 16:04:45 UTC
Previous filing
21 Feb 2023
Next filing
20 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Tax liability $1,956,733 -12,683 -43% $154.28 16,751 28 Feb 2023 Direct
transaction ABBV Common Stock, $0.01 par value Sale $2,309,982 -15,092 -90% $153.06 1,659 01 Mar 2023 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale $130,373 -850 -51% $153.38 809 01 Mar 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.37 to $153.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.37 to $153.47, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

The sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).